First Tracks Biotherapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
First Tracks Biotherapeutics reported Q2 2026 financial results, highlighting progress in its ANB033 clinical trials for celiac disease and eosinophilic esophagitis, alongside a positive FDA Fast Track designation.